Attached files

file filename
EX-99.1 - Advaxis, Inc.ex99-1.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): January 8, 2016

 

ADVAXIS, INC.

(Exact Name of Registrant as Specified in Charter)

 

Delaware   000-28489   02-0563870

(State or Other Jurisdiction

of Incorporation)

 

(Commission
File Number)

  (IRS Employer
Identification No.)

 

305 College Road East

Princeton, New Jersey, 08540

(Address of Principal Executive Offices)

 

(609) 452-9813

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[  ] Written communications pursuant to Rule 425 under the Securities Act.
   
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
   
[  ] Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
   
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

 

 

 

 
   

 

Item 7.01 Regulation FD Disclosures.

 

A copy of the press release of Advaxis, Inc. (the “Company”) dated January 8, 2016 relating to the announcement discussed in Item 8.01 below is attached hereto as Exhibit 99.1.

 

The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 8.01 Other Events.

 

On January 8, 2016, the Company issued a press release announcing its 2016 business outlook. The press release also outlined various regulatory, clinical, business and operational milestones for 2015.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

The following exhibits are furnished as a part of this report:

 

Exhibit
Number
  Description
     
99.1   Press Release dated January 8, 2016

 

 
   

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ADVAXIS, INC.
  (Registrant)
     
  By: /s/ Daniel J. O’Connor
    Daniel J. O’Connor
    President and Chief Executive Officer

 

Date: January 11, 2016

 

 
   

 

INDEX TO EXHIBITS

 

Exhibit    
Number   Description
     
99.1   Press release issued by the Company on January 8, 2016.